Glenmark shares rise 2% on US cancer drug launch
Click to view quick news summary (Spoiler)
Glenmark launched an authorized generic of Pfizer's INLYTA (axitinib) in the United States, with 1 mg and 5 mg tablets now available.
According to reports from CNBC TV18 and Business Standard, Glenmark Pharmaceuticals announced that its US arm has launched generic Axitinib Tablets, an authorized version of Pfizer's cancer drug INLYTA. The Mumbai-based company's American subsidiary, Glenmark Pharmaceuticals Inc., USA, launched the 1 mg and 5 mg tablets following regulatory approval. This product represents an authorized generic version of INLYTA® (axitinib) tablets, which was originally developed by Pfizer for cancer therapy treatment. The launch signifies Glenmark's ongoing efforts to provide affordable medication options to patients in the US market, with the company emphasizing its commitment to expanding access to quality, affordable medicines for patients in the United States.
Market Opportunity
As reported by CNBC TV18 and Business Standard, the commercial potential of this drug is significant based on IQVIA® sales data for the 12 months ending September 2026. US annual sales of INLYTA® Tablets were approximately $538.4 million during this period. INLYTA is used in Kidney Cancer (Renal Cell Carcinoma) treatment, functioning as a standalone treatment when prior systemic therapy has been unsuccessful, or as a first-line treatment for advanced disease in combination with immunotherapy agents such as pembrolizumab or avelumab. The introduction of Glenmark's generic version is expected to offer a cost-effective alternative to patients and healthcare providers, potentially impacting the market dynamics for this category of oncology medication.
Stock Performance
According to CNBC TV18, Glenmark Pharma shares gained up to 2% on Monday, November 16, following the drug launch announcement. The stock has demonstrated strong performance this year, with shares jumping by over 30% so far, reaching ₹2,643 per share. The stock's 52-week high stands at ₹2,714.00, indicating continued investor confidence in the company's growth prospects. The launch is anticipated to influence the competitive landscape of the oncology drug market in the US, with analysts monitoring the impact on Glenmark's market share and broader implications for pricing and accessibility in the oncology segment.
Recent Financial Results
As reported by CNBC TV18, the company reported its quarterly results on November 5, showing mixed performance in the September-ended quarter. The company recorded a net profit drop of 56.7% year on year to ₹264 crore, compared with ₹610 crore last year. Revenue fell 29.8% to ₹4,247.3 crore from ₹6,046.8 crore a year earlier. Earnings before interest, tax, depreciation and amortisation (EBITDA) declined 63.4% to ₹864 crore from ₹2,360 crore, while the EBITDA margin narrowed to 20% from 39% in Q2 FY26.
Management Commentary
According to CNBC TV18 and Business Standard, Marc Kikuchi, President & Business Head, North America, commented on the launch, stating that "The launch of Axitinib tablets reinforces Glenmark's commitment to expanding access to quality, affordable medicines for patients in the United States. By adding this important product to our portfolio, we continue to strengthen our focus on addressing the evolving needs of patients and healthcare providers." Kikuchi emphasized the company's commitment to enhancing access to quality healthcare, highlighting the strategic importance of this product addition in addressing the evolving needs of patients and healthcare providers.